DOCSLIB.ORG

Supplemental Material a a H a a H - - - - - CD3 SSC FSC SSC SSC SSC

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplemental Material a a H a a H - - - - - CD3 SSC FSC SSC SSC SSC Single cell analysis of RA synovial B cells reveals a spectrum of ectopic lymphoid B cell activation and hypermutation characterized by NR4A nuclear receptor expression Supplemental material A A H A A H - - - - - CD3 SSC FSC SSC SSC SSC FSC-A FSC-W SSC-W DAPI CD45 CD19 B RA172_SYN RA195_SYN 105 5 SM USM CD45+ 10 SM USM CD45+ 4 105 10 DN N 105 4 DN N 10 37.5 49.3 4 BV605 3 4 49.1 10 10 10 CD27 3 7.2 10 1.1 3.3 CD27 CD27 3 2 3 10 10 57.6 CD3 2 31.6 10 10 0 CD3 PECy5 0 10.8 2 2 21.6 37.2 10 5.5 2 3 4 5 10 0 0 10 10 10 10 0 102 103 104 105 IgDIgD FITC 0 IgD 5 0 102 103 104 105 10 0 102 103 104 105 105 CD19CD19 PEDazzle594 CD19 - hi 4 - hi CD24 CD27 10 CD24 CD27 4 10 CD3 2.4 1.9 BV605 103 103 CD27 CD27 CD27 102 102 0 0 47.5 39.0 0 102 103 104 105 2 3 4 5 CD24 A647 0 10 10 10 10 CD24 CD24 RA221_SYN RA134_SYN 5 10 SM USM 105 SM USM CD45+ 104 DN N CD45+ 4 DN N 10 CD24 105 21.8 105 BV605 3 4.9 BV605 41.6 10 103 37.4 1.7 4 4 32.1 CD27 CD27 10 CD27 10 CD27 2 2 10 38.6 10 3 0 3 10CD3 10 0 12.1 34.3 CD3 48.7 CD3 PECy5 CD3 PECy5 2 3 4 5 0 10 10 10 10 0 102 103 104 105 2 20.8 2 2.7 10 IgD FITC 10 IgD FITC 0 0 IgD 5 5 2 3 4 5 10 0 102 103 104 105 10 0 10 10 10 10 CD19 PEDazzle594 CD19 PEDazzle594 CD19 - hi CD19 CD24 CD27 104 104 2.6 7.6 CD24-CD27hi BV605 BV605 103 103 CD27 CD27 CD27 CD27 2 102 10 0 0 60.8 2 3 4 5 0 102 103 104 105 0 10 10 10 10 CD24 A647 CD24CD24 A647 CD24 RA134_BLD SM USM CD45+ fig. S1. Flow cytometry schema for sorting and DN N analysis of B cells. (A) Flow cytometry gating strategy CD24 for sorting of B cells. (B) Flow cytometry analysis for CD27 B cell phenotyping for each sample. CD27 vs. IgD plot CD3 shows % of switched memory (SM), un-switched memory (USM), double negative (DN) and Naïve (N). - hi IgD CD27 vs. CD24 identify CD24 CD27 plasmablast. CD19 CD24-CD27hi CD27 CD24 A B C D Isotype BCR not recovered M BCR recovered D A G K L N/A # of cell E F Plasma (ii) IGHA Plasma(ii) ● IGHD Plasma (i) IGHG Plasma(i) ● IGHM memory NR4A+ ● LMNA+ Naive(iii) ● NR4A+ Naive(ii) ● Naïve (iii) Memory ● Naïve (ii) LMNA+ ● Naïve (i) −2.5 0.0 2.5 5.0 7.5 % point increase in SHM (vs Naive) fig. S2. Evidence of class-switched recombination and clonal expansion in RA synovium. (A) Bar graph showing percentage of cells with productive V-J spanning pair out of total barcode recovered per sample, RA134 PBL (1559 cells), RA134 SYN (694 cells), RA172 SYN (457 cells), RA195 SYN (1240 cells) and RA221 SYN (607 cells). (B) Bar graph displaying percentage recovery of paired heavy-light chain, single heavy or light chain or non-canonical pairing out of total, RA134 PBL (1348 cells), RA134 SYN (187 cells), RA172 SYN (140 cells), RA195 SYN (850 cells) and RA221 SYN (225 cells). (C) Bar graph showing number of cells where BCR was recovered or not recovered per cluster and per sample. (D) Pairing of heavy and light chains in RA195 SYN. Each point represents a cell. Clones that occurred 2 or more times are shown. The amino acid sequence of the CDR3 of the heavy and light chains are shown below and the left of the x and y axes, respectively. The color of the label represents the isotype. (E) Bar graphs depicting number of cells expressing IGHA, IGHD, IGHG and IGHM per B cell cluster. (F) Difference in SHM rate in cell populations vs Naive(i) using linear mixed effect models with capture:cluster random effect. A B Immediate early genes early BCR signaling B � NF signaling DZ CD40 signaling MYC fig. S3. (A) Heatmap display log2 fold change of immediate early genes, NF�B signaling genes, CD40 signaling genes and MYC genes (Ye et al, 2010; Ollila et al, 2003; Holmes et al, 2020). (B) NR4A+ cluster maintains expression of some DZ genes. Heatmap display log2 fold change of BCR signaling genes and genes associated with DZ GC B cells in each B cell cluster (Holmes et al, 2020). 100X 200X CD20 IgD PCNA CD21 CD20 CD138 CD3 CD68 CD20 fig. S4. Immunofluorescent staining of synovial tissue samples used for B cell single cell RNA sequencing. 5 µm synovial serial sections were stained with Hematoxylin and Eosin or antibodies specific for proliferating cell nuclear antigen (PCNA, white), IgD (green), and CD20 (red) to detect large CD20+IgD-PCNA+ germinal center B cells. Synovial sections were stained with a combination of antibodies specific for CD20 and CD21 to detect CD21+ follicular dendritic cells (red) in germinal centers populated by CD20+ B cells (green). We also stain paraffin sections with antibodies to detect CD138+ plasma cells (red), CD3+ T cells (green), CD68+ macrophages (white), and CD20+ B cells (blue) in the ELS in the inflamed synovia of RA patient. Representative 200x magnification pictures are shown. Scale bars represent 100 µm. A B non-zero expressing cell (% of each subset) Log2FC C D Log2FC non-zero expressing cell (% of each subset) fig. S5. Single cell RNA sequencing data of synovial B cells from AMP phase I (n= 14 RA, Zhang et al., 2019) were re-analyzed and B cell subsets parallel to current study were identified using a supervised classification technique SingleR. (A) Heatmap displays log2 fold change of cytokine and chemokine receptors in each B cell subset. (B) Bar graphs display percentage of cells of each subset that express CXCR5, CCR7, CXCR4 or CCR6. (C) Heatmap displays log2 fold change of cytokines and chemokines in each B cell subset. (D) Bar graph represent percentage of cells of each subset that express IL6, TNFSF9, CD70, TGFB1, CCL5 or LTB. A Cluster CD83 NR4A2 NR4A1 FOSB KLF6 PPP1R15A Dimension1 score FOS B CD69 NR4A1 DUSP1 DUSP2 CD83 ZFP36 6 NR4A2 BTG2 NENormalized Expression Cluster NR4A1 EIF1 6 Naive(i) FOSBCD83 DUSP1CD83 4 KLF6 NR4A2 NR4A2 4 Naive(iii) NR4A1 CDKN1ANR4A1 PPP1R15AFOSB NR4A3FOSB 2 Naive(ii) FOS KLF6 CREMKLF6 2 CD69 PPP1R15A NFKBIDPPP1R15A 0 NR4A+ DUSP2FOS GPR183FOS ZFP36CD69 CD69 0 PC1 Naive(i) DUSP2 NormalizedSRGN Expression Cluster BTG2 JUNDDUSP2 20 Naive(ii) EIF1 ZFP36 6 ZFP36 TXNIP CD79B DUSP1BTG2 NormalizedDNAJA1BTG2 Expression ClusterNormalizedNaive(i) Expression Cluster10 Naive(iii) EIF1 6YPEL5EIF1 6 NR4A+ CDKN1ADUSP1 4 DUSP1 Naive(i)Naive(iii) 6 Naive(i) 4ZNF331 Naive(iii)4 0 NR4A3CDKN1A 2 SLC2A3CDKN1A Naive(ii) Expression (logcounts) Naive(iii) CREMNR4A3 2KDM6BNR4A3 Naive(ii)2 Naive(ii)−10 NFKBIDCREM 0 CREM NR4A+ 4 NFKBID 0LY9 NFKBID NR4A+0 NR4A+−20 GPR183GPR183 IGHG1 SRGN GPR183 PC1 PC1 SRGN MCL1SRGN 2 JUNDJUND IDS JUND 2020 20 DNAJA1DNAJA1 DNAJA1 YPEL5YPEL5 MTRNR2L12YPEL5 1010 10 ZNF331ZNF331 LMNAZNF331 0 0 0 SLC2A3 TXNIPSLC2A3 0 SLC2A3KDM6B TCL1AKDM6B −−1010 −10 0 −10 10 20 −10 0 10 20 KDM6BLY9 RCSD1LY9 −20 PC1 LY9 IGHG1 −20 −20 IGHG1MCL1 IGHMIGHG1 IDS RP11MCL1−160E2.6 MCL1MTRNR2L12 TMSB10IDS IDS LMNA CD79BMTRNR2L12 MTRNR2L12TXNIP LMNA LMNATCL1A FCER2TXNIP TXNIPRCSD1 PLPP5TCL1A IGHM RCSD1 TCL1ARP11−160E2.6 IGHM RCSD1TMSB10 RP11−160E2.6 IGHMCD79B TMSB10 RP11−FCER2160E2.6 CD79B TMSB10PLPP5 FCER2 CD79B PLPP5 FCER2 DUSP1 PLPP5 JUN JUNB BTG1 CXCR4 C Dimension2 score ZFP36L2 LY9 JUN DUSP1 VPS37B 7.5 MT−ND4 DUSP1 MT−ND5 JUN NCF1 NENormalized Expression5.0 Cluster JUNB CD37DUSP1 6 BTG1 IGHMJUN Memory CXCR4 IGHDJUNB 4 2.5 Naive(iii) ZFP36L2 TCL1ABTG1 LY9 FAM129CCXCR4 2 NR4A+ VPS37B BACH2ZFP36L2 0 LMNA+ MT−ND4 LY9 0.0 FOXP1VPS37B PC2 MT−ND5 NormalizedGADD45BMT Expression−ND4 Cluster LMNA+ NCF1 RPS19 20 Memory MT−ND5 S100A6 HOPX CD37 6 RPL13ANCF1 NormalizedMemory Expression7.5 Cluster10 Naive(iii) IGHM VIMCD37 6 NR4A+ IGHD 4 CD99IGHM Naive(iii) Memory0 TCL1A S100A10 4 Naive(iii) 2 IGHD NR4A+ Expression (logcounts) 5.0 −10 FAM129C CRIP2TCL1A 2 NR4A+ BACH2 0 S100A6FAM129C LMNA+ −20 FOXP1 S100A4BACH2 0 LMNA+ PC2 2.5 GADD45B LGALS1FOXP1 PC2 RPS19 CRIP1GADD45B 20 RPL13A LMNARPS19 20 ITGB1RPL13A 10 0.0 VIM HLAVIM−C 10 CD99 CD99 0 0 S100A10 HLAS100A10−A IGHA1 −10 −10 −10 0 10 −10 0 10 CRIP2 ACTBCRIP2 S100A6 S100A6 −20 PC2 ACTG1S100A4 −20 S100A4 GAPDHLGALS1 LGALS1 SH3BGRL3CRIP1 CRIP1 HOPXLMNA LMNA PDE4DITGB1 ITGB1 HLA−C HLA−C HLA−A HLA−A IGHA1 IGHA1 ACTB ACTB ACTG1 ACTG1 GAPDH GAPDH SH3BGRL3 SH3BGRL3 HOPX HOPX PDE4D PDE4D D fig. S6. A gene expression continuum from naïve to NR4A+ B cells. (A) Principal component analysis projecting gene expression data of Naïve (i), Naïve (ii), Naïve (iii), NR4A+, LMNA+ and memory B cell subsets onto two dimensional space. (B) Heatmap display expression of top 40 loading genes for dimension 1 with increasing score from Naïve (i), Naïve (ii), Naïve (iii) and NR4A+ subset. Plots on the right show example of genes increase (NR4A1, DUSP1) or decrease (TXNIP, CD79B) as cells transition from naïve to NR4A+ state. (C) Heatmap display expression of top 40 loading genes for dimension 2 with increasing score from Naïve (iii), NR4A+, LMNA+ and memory subset. Plots on the right show example of genes decrease (JUN, DUSP1) or increase (S100A6, HOPX) as cells transition from NR4A+ to memory state.
Load more

Recommended publications
  • Ubiquitin-Conjugating Enzyme UBE2J1 Negatively Modulates
    Feng et al. Virology Journal (2018) 15:132 https://doi.org/10.1186/s12985-018-1040-5 RESEARCH Open Access Ubiquitin-conjugating enzyme UBE2J1 negatively modulates interferon pathway and promotes RNA virus infection Tingting Feng1, Lei Deng1, Xiaochuan Lu1, Wen Pan1, Qihan Wu2* and Jianfeng Dai1,2* Abstract Background: Viral infection activates innate immune pathways and interferons (IFNs) play a pivotal role in the outcome of a viral infection. Ubiquitin modifications of host and viral proteins significantly influence the progress of virus infection. Ubiquitin-conjugating enzyme E2s (UBE2) have the capacity to determine ubiquitin chain topology and emerge as key mediators of chain assembly. Methods: In this study, we screened the functions of 34 E2 genes using an RNAi library during Dengue virus (DENV) infection. RNAi and gene overexpression approaches were used to study the gene function in viral infection and interferon signaling. Results: We found that silencing UBE2J1 significantly impaired DENV infection, while overexpression of UBE2J1 enhanced DENV infection. Further studies suggested that type I IFN expression was significantly increased in UBE2J1 silenced cells and decreased in UBE2J1 overexpressed cells. Reporter assay suggested that overexpression of UBE2J1 dramatically suppressed RIG-I directed IFNβ promoter activation. Finally, we have confirmed that UBE2J1 can facilitate the ubiquitination and degradation of transcription factor IFN regulatory factor 3 (IRF3). Conclusion: These results suggest that UBE2 family member UBE2J1 can negatively regulate type I IFN expression, thereby promote RNA virus infection. Keywords: UBE2J1, Dengue virus, Interferons, IRF3, K48 ubiquitination Background antiviral responses [3]. IFN-α/β regulates the synthesis Dengue virus (DENV), transmitted by Aedes aegypti and of antiviral proteins and immunoregulatory factors Aedes albopicuts, causes an emerging tropical disease through the JAK/STAT signaling pathway [4, 5].
    [Show full text]
  • MARCH5 Requires MTCH2 to Coordinate Proteasomal Turnover of the MCL1:NOXA Complex
    Cell Death & Differentiation (2020) 27:2484–2499 https://doi.org/10.1038/s41418-020-0517-0 ARTICLE MARCH5 requires MTCH2 to coordinate proteasomal turnover of the MCL1:NOXA complex 1,2 1,2,5 1,2 1,2 1,2,3 1,2 Tirta Mario Djajawi ● Lei Liu ● Jia-nan Gong ● Allan Shuai Huang ● Ming-jie Luo ● Zhen Xu ● 4 1,2 1,2 1,2 Toru Okamoto ● Melissa J. Call ● David C. S. Huang ● Mark F. van Delft Received: 3 July 2019 / Revised: 6 February 2020 / Accepted: 7 February 2020 / Published online: 24 February 2020 © The Author(s) 2020. This article is published with open access Abstract MCL1, a BCL2 relative, is critical for the survival of many cells. Its turnover is often tightly controlled through both ubiquitin-dependent and -independent mechanisms of proteasomal degradation. Several cell stress signals, including DNA damage and cell cycle arrest, are known to elicit distinct E3 ligases to ubiquitinate and degrade MCL1. Another trigger that drives MCL1 degradation is engagement by NOXA, one of its BH3-only protein ligands, but the mechanism responsible has remained unclear. From an unbiased genome-wide CRISPR-Cas9 screen, we discovered that the ubiquitin E3 ligase MARCH5, the ubiquitin E2 conjugating enzyme UBE2K, and the mitochondrial outer membrane protein MTCH2 co- — fi 1234567890();,: 1234567890();,: operate to mark MCL1 for degradation by the proteasome speci cally when MCL1 is engaged by NOXA. This mechanism of degradation also required the MCL1 transmembrane domain and distinct MCL1 lysine residues to proceed, suggesting that the components likely act on the MCL1:NOXA complex by associating with it in a specific orientation within the mitochondrial outer membrane.
    [Show full text]
  • Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma
    cancers Article Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma Nabanita Mukherjee 1, Carol M. Amato 2 , Jenette Skees 1, Kaleb J. Todd 1, Karoline A. Lambert 1, William A. Robinson 2, Robert Van Gulick 2, Ryan M. Weight 2, Chiara R. Dart 2, Richard P. Tobin 3, Martin D. McCarter 3, Mayumi Fujita 1,4,5 , David A. Norris 1,4 and Yiqun G. Shellman 1,5,* 1 Department of Dermatology, School of Medicine, University of Colorado Anschutz Medical Campus, Mail Stop 8127, Aurora, CO 80045, USA; [email protected] (N.M.); [email protected] (J.S.); [email protected] (K.J.T.); [email protected] (K.A.L.); [email protected] (M.F.); [email protected] (D.A.N.) 2 Division of Medical Oncology, School of Medicine, University of Colorado Anschutz Medical Campus, Mail Stop 8117, Aurora, CO 80045, USA; [email protected] (C.M.A.); [email protected] (W.A.R.); [email protected] (R.V.G.); [email protected] (R.M.W.); [email protected] (C.R.D.) 3 Division of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; [email protected] (R.P.T.); [email protected] (M.D.M.) 4 Dermatology Section, Department of Veterans Affairs Medical Center, Denver, CO 80220, USA 5 Gates Center for Regenerative Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA * Correspondence: [email protected]; Tel.: +1-303-724-4034; Fax: +1-303-724-4048 Received: 30 June 2020; Accepted: 31 July 2020; Published: 5 August 2020 Abstract: There is an urgent need to develop treatments for patients with melanoma who are refractory to or ineligible for immune checkpoint blockade, including patients who lack BRAF-V600E/K mutations.
    [Show full text]
  • The E2 Ubiquitin-Conjugating Enzyme UBE2J1 Is Required for Spermiogenesis in Mice
    The E2 Ubiquitin-conjugating Enzyme UBE2J1 Is Required for Spermiogenesis in Mice The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Koenig, Paul-Albert, Peter K. Nicholls, Florian I. Schmidt, Masatoshi Hagiwara, Takeshi Maruyama, Galit H. Frydman, Nicki Watson, David C. Page, and Hidde L. Ploegh. “The E2 Ubiquitin-Conjugating Enzyme UBE2J1 Is Required for Spermiogenesis in Mice.” Journal of Biological Chemistry 289, no. 50 (October 15, 2014): 34490–34502. © 2014 American Society for Biochemistry and Molecular Biology, Inc. (ASBMB) As Published http://dx.doi.org/10.1074/jbc.M114.604132 Publisher American Society for Biochemistry and Molecular Biology (ASBMB) Version Author's final manuscript Citable link http://hdl.handle.net/1721.1/108038 Terms of Use Creative Commons Attribution-Noncommercial-Share Alike Detailed Terms http://creativecommons.org/licenses/by-nc-sa/4.0/ Male Ube2j1-/- mice are sterile The E2 Ubiquitin Conjugating Enzyme UBE2J1 is Required for Spermiogenesis in Mice Paul-Albert Koenig1, Peter K. Nicholls1, Florian I. Schmidt1, Masatoshi Hagiwara1, Takeshi Maruyama1, Galit H. Frydman2, Nicki Watson1, David C. Page1,3,4, Hidde L. Ploegh1,3 1 Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA 2 Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA 02139, USA 3 Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA 4 Howard Hughes Medical Institute, Cambridge, MA 02142,
    [Show full text]
  • Synergy of Bcl2 and Histone Deacetylase Inhibition Against Leukemic Cells from Cutaneous T-Cell Lymphoma Patients Benoit Cyrenne
    Yale University EliScholar – A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine January 2018 Synergy Of Bcl2 And Histone Deacetylase Inhibition Against Leukemic Cells From Cutaneous T-Cell Lymphoma Patients Benoit Cyrenne Follow this and additional works at: https://elischolar.library.yale.edu/ymtdl Recommended Citation Cyrenne, Benoit, "Synergy Of Bcl2 And Histone Deacetylase Inhibition Against Leukemic Cells From Cutaneous T-Cell Lymphoma Patients" (2018). Yale Medicine Thesis Digital Library. 3388. https://elischolar.library.yale.edu/ymtdl/3388 This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, please contact [email protected]. i Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients A Thesis Submitted to the Yale University School of Medicine in Partial Fulfillment of the Requirements for the Degree of Doctor of Medicine Benoit M. Cyrenne 2018 ii SYNERGY OF BCL2 AND HISTONE DEACETYLASE INHIBITION AGAINST LEUKEMIC CELLS FROM CUTANEOUS T-CELL LYMPHOMA PATIENTS. Benoit Cyrenne, Julia Lewis, Jason Weed, Kacie Carlson, Fatima Mirza, Francine Foss, and Michael Girardi. Department of Dermatology, Yale University, School of Medicine, New Haven, CT. The presence and degree of peripheral blood involvement in patients with cutaneous T-cell lymphoma (CTCL) portend a worse clinical outcome. Available systemic therapies for CTCL may variably decrease tumor burden and improve quality of life, but offer limited effects on survival; thus, novel approaches to the treatment of advanced stages of this non-Hodgkin lymphoma are clearly warranted.
    [Show full text]
  • BCL-2 Family Proteins: Changing Partners in the Dance Towards Death
    Cell Death and Differentiation (2018) 25, 65–80 OPEN Official journal of the Cell Death Differentiation Association www.nature.com/cdd Review BCL-2 family proteins: changing partners in the dance towards death Justin Kale1, Elizabeth J Osterlund1,2 and David W Andrews*,1,2,3 The BCL-2 family of proteins controls cell death primarily by direct binding interactions that regulate mitochondrial outer membrane permeabilization (MOMP) leading to the irreversible release of intermembrane space proteins, subsequent caspase activation and apoptosis. The affinities and relative abundance of the BCL-2 family proteins dictate the predominate interactions between anti-apoptotic and pro-apoptotic BCL-2 family proteins that regulate MOMP. We highlight the core mechanisms of BCL-2 family regulation of MOMP with an emphasis on how the interactions between the BCL-2 family proteins govern cell fate. We address the critical importance of both the concentration and affinities of BCL-2 family proteins and show how differences in either can greatly change the outcome. Further, we explain the importance of using full-length BCL-2 family proteins (versus truncated versions or peptides) to parse out the core mechanisms of MOMP regulation by the BCL-2 family. Finally, we discuss how post- translational modifications and differing intracellular localizations alter the mechanisms of apoptosis regulation by BCL-2 family proteins. Successful therapeutic intervention of MOMP regulation in human disease requires an understanding of the factors that mediate the major binding interactions between BCL-2 family proteins in cells. Cell Death and Differentiation (2018) 25, 65–80; doi:10.1038/cdd.2017.186; published online 17 November 2017 The membrane plays an active role in most BCL-2 family interactions by changing the affinities and local relative abundance of these proteins.
    [Show full text]
  • 1 Supporting Information for a Microrna Network Regulates
    Supporting Information for A microRNA Network Regulates Expression and Biosynthesis of CFTR and CFTR-ΔF508 Shyam Ramachandrana,b, Philip H. Karpc, Peng Jiangc, Lynda S. Ostedgaardc, Amy E. Walza, John T. Fishere, Shaf Keshavjeeh, Kim A. Lennoxi, Ashley M. Jacobii, Scott D. Rosei, Mark A. Behlkei, Michael J. Welshb,c,d,g, Yi Xingb,c,f, Paul B. McCray Jr.a,b,c Author Affiliations: Department of Pediatricsa, Interdisciplinary Program in Geneticsb, Departments of Internal Medicinec, Molecular Physiology and Biophysicsd, Anatomy and Cell Biologye, Biomedical Engineeringf, Howard Hughes Medical Instituteg, Carver College of Medicine, University of Iowa, Iowa City, IA-52242 Division of Thoracic Surgeryh, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada-M5G 2C4 Integrated DNA Technologiesi, Coralville, IA-52241 To whom correspondence should be addressed: Email: [email protected] (M.J.W.); yi- [email protected] (Y.X.); Email: [email protected] (P.B.M.) This PDF file includes: Materials and Methods References Fig. S1. miR-138 regulates SIN3A in a dose-dependent and site-specific manner. Fig. S2. miR-138 regulates endogenous SIN3A protein expression. Fig. S3. miR-138 regulates endogenous CFTR protein expression in Calu-3 cells. Fig. S4. miR-138 regulates endogenous CFTR protein expression in primary human airway epithelia. Fig. S5. miR-138 regulates CFTR expression in HeLa cells. Fig. S6. miR-138 regulates CFTR expression in HEK293T cells. Fig. S7. HeLa cells exhibit CFTR channel activity. Fig. S8. miR-138 improves CFTR processing. Fig. S9. miR-138 improves CFTR-ΔF508 processing. Fig. S10. SIN3A inhibition yields partial rescue of Cl- transport in CF epithelia.
    [Show full text]
  • The AAA-Atpase P97 Is Essential for Outer Mitochondrial Membrane Protein Turnover
    MBoC | ARTICLE The AAA-ATPase p97 is essential for outer mitochondrial membrane protein turnover Shan Xu a, b,* , Guihong Peng a, b,* , Yang Wang a, c , Shengyun Fang a, c , and Mariusz Karbowskia, b a Center for Biomedical Engineering and Technology, University of Maryland, Baltimore, MD 21201; b Department of Biochemistry & Molecular Biology, c Department of Physiology, University of Maryland School of Medicine, Baltimore, MD 21201 ABSTRACT Recent studies have revealed a role for the ubiquitin/proteasome system in the Monitoring Editor regulation and turnover of outer mitochondrial membrane (OMM)-associated proteins. Al- Benjamin Glick though several molecular components required for this process have been identifi ed, the University of Chicago mechanism of proteasome-dependent degradation of OMM-associated proteins is currently Received: Sep 3 , 2010 unclear. We show that an AAA-ATPase, p97, is required for the proteasomal degradation of Revised: Oct 26 , 2010 Mcl1 and Mfn1, two unrelated OMM proteins with short half-lives. A number of biochemical Accepted: Nov 18 , 2010 assays, as well as imaging of changes in localization of photoactivable GFP-fused Mcl1, re- vealed that p97 regulates the retrotranslocation of Mcl1 from mitochondria to the cytosol, prior to, or concurrent with, proteasomal degradation. Mcl1 retrotranslocation from the OMM depends on the activity of the ATPase domain of p97. Furthermore, p97-mediated retrotranslocation of Mcl1 can be recapitulated in vitro, confi rming a direct mitochondrial role for p97. Our results establish p97 as a novel and essential component of the OMM-associated protein degradation pathway. INTRODUCTION Mitochondria are the primary site of energy production in animal such as mitochondrial membrane dynamics.
    [Show full text]
  • UBE2J1 Sirna Set I UBE2J1 Sirna Set I
    Catalog # Aliquot Size U225-911-05 3 x 5 nmol U225-911-20 3 x 20 nmol U225-911-50 3 x 50 nmol UBE2J1 siRNA Set I siRNA duplexes targeted against three exon regions Catalog # U225-911 Lot # Z2109-26 Specificity Formulation UBE2J1 siRNAs are designed to specifically knock-down The siRNAs are supplied as a lyophilized powder and human UBE2J1 expression. shipped at room temperature. Product Description Reconstitution Protocol UBE2J1 siRNA is a pool of three individual synthetic siRNA Briefly centrifuge the tubes (maximum RCF 4,000g) to duplexes designed to knock-down human UBE2J1 mRNA collect lyophilized siRNA at the bottom of the tube. expression. Each siRNA is 19-25 bases in length. The gene Resuspend the siRNA in 50 µl of DEPC-treated water accession number is BC013973. (supplied by researcher), which results in a 1x stock solution (10 µM). Gently pipet the solution 3-5 times to mix Gene Aliases and avoid the introduction of bubbles. Optional: aliquot CGI-76; HSPC153; HSPC205; HSU93243; NCUBE-1; NCUBE1; 1x stock solutions for storage. UBC6; Ubc6p Related Products Storage and Stability The lyophilized powder is stable for at least 4 weeks at Product Name Catalog Number room temperature. It is recommended that the UBE2E3 (UBCH9) Protein U219-30H lyophilized and resuspended siRNAs are stored at or UBE2F Protein U220-30H below -20oC. After resuspension, siRNA stock solutions ≥2 UBE2G1 (UBC7) Protein U221-30H µM can undergo up to 50 freeze-thaw cycles without UBE2H Protein U223-30H significant degradation. For long-term storage, it is UBE2I Protein U224-30H recommended that the siRNA is stored at -70oC.
    [Show full text]
  • Multi-Modal Effects of 1B3, a Novel Synthetic Mir-193A-3P Mimic, Support Strong Potential for Therapeutic Intervention in Oncology
    www.oncotarget.com Oncotarget, 2021, Vol. 12, (No. 5), pp: 422-439 Research Paper Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology Bryony J. Telford1, Sanaz Yahyanejad1, Thijs de Gunst1, Harm C. den Boer1, Rogier M. Vos1, Marieke Stegink1, Marion T.J. van den Bosch1, Mir Farshid Alemdehy1, Laurens A.H. van Pinxteren1, Roel Q.J. Schaapveld1 and Michel Janicot1 1InteRNA Technologies BV, Utrecht, The Netherlands Correspondence to: Michel Janicot, email: [email protected] Keywords: miR-193a-3p; microRNA mimic; microRNA delivery in vivo; pleiotropic mechanism of microRNA Received: October 16, 2020 Accepted: February 01, 2021 Published: March 02, 2021 Copyright: © 2021 Telford et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Compelling evidence demonstrates that miR-193a-3p is a tumor suppressor microRNA in many cancer types, and its reduced expression is linked to cancer initiation and progression, metastasis, and therapy resistance. However, its mechanism of action is not consistently described between studies, and often contradicts the pleiotropic role of a microRNA in manipulating several different mRNA targets. We therefore comprehensively investigated miRNA-193a-3p's mode of action in a panel of human cancer cell lines, with a variety of genetic backgrounds, using 1B3, a synthetic microRNA mimic. Interestingly, the exact mechanism through which 1B3 reduced cell proliferation varied between cell lines. 1B3 efficiently reduced target gene expression, leading to reduced cell proliferation/survival, cell cycle arrest, induction of apoptosis, increased cell senescence, DNA damage, and inhibition of migration.
    [Show full text]
  • Anti-NOXA Antibody (ARG64942)
    Product datasheet [email protected] ARG64942 Package: 100 μg, 50 μg anti-NOXA antibody Store at: -20°C Summary Product Description Goat Polyclonal antibody recognizes NOXA Tested Reactivity Hu Tested Application WB Host Goat Clonality Polyclonal Isotype IgG Target Name NOXA Antigen Species Human Immunogen C-TQLRRFGDKLNFRQK Conjugation Un-conjugated Alternate Names NOXA; APR; Phorbol-12-myristate-13-acetate-induced protein 1; PMA-induced protein 1; Immediate- early-response protein APR; Protein Noxa Application Instructions Application table Application Dilution WB 0.03 - 0.1 µg/ml Application Note WB: Recommend incubate at RT for 1h. * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 6 kDa Properties Form Liquid Purification Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. Buffer Tris saline (pH 7.3), 0.02% Sodium azide and 0.5% BSA Preservative 0.02% Sodium azide Stabilizer 0.5% BSA Concentration 0.5 mg/ml Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/2 Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Database links GeneID: 5366 Human Swiss-port # Q13794 Human Gene Symbol PMAIP1 Gene Full Name phorbol-12-myristate-13-acetate-induced protein 1 Function Promotes activation of caspases and apoptosis.
    [Show full text]
  • Knockout of Vdac1 Activates Hypoxia-Inducible Factor Through
    Brahimi-Horn et al. Cancer & Metabolism (2015) 3:8 DOI 10.1186/s40170-015-0133-5 Cancer & Metabolism RESEARCH Open Access Knockout of Vdac1 activates hypoxia- inducible factor through reactive oxygen species generation and induces tumor growth by promoting metabolic reprogramming and inflammation M. Christiane Brahimi-Horn1†, Sandy Giuliano1†, Estelle Saland2, Sandra Lacas-Gervais3, Tatiana Sheiko4, Joffrey Pelletier1, Isabelle Bourget5, Frédéric Bost6, Chloé Féral5, Etienne Boulter5, Michel Tauc7, Mircea Ivan8, Barbara Garmy-Susini9, Alexandra Popa10, Bernard Mari10, Jean-Emmanuel Sarry2, William J. Craigen4, Jacques Pouysségur1,11 and Nathalie M. Mazure1* Abstract Background: Mitochondria are more than just the powerhouse of cells; they dictate if a cell dies or survives. Mitochondria are dynamic organelles that constantly undergo fusion and fission in response to environmental conditions. We showed previously that mitochondria of cells in a low oxygen environment (hypoxia) hyperfuse to form enlarged or highly interconnected networks with enhanced metabolic efficacy and resistance to apoptosis. Modifications to the appearance and metabolic capacity of mitochondria have been reported in cancer. However, the precise mechanisms regulating mitochondrial dynamics and metabolism in cancer are unknown. Since hypoxia plays a role in the generation of these abnormal mitochondria, we questioned if it modulates mitochondrial function. The mitochondrial outer-membrane voltage-dependent anion channel 1 (VDAC1) is at center stage in regulating metabolism and apoptosis. We demonstrated previously that VDAC1 was post-translationally C-terminal cleaved not only in various hypoxic cancer cells but also in tumor tissues of patients with lung adenocarcinomas. Cells with enlarged mitochondria and cleaved VDAC1 were also more resistant to chemotherapy-stimulated cell death than normoxic cancer cells.
    [Show full text]